BIOTON Past Earnings Performance
Past criteria checks 4/6
BIOTON has been growing earnings at an average annual rate of 33.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 1.6% per year. BIOTON's return on equity is 0.4%, and it has net margins of 1.3%.
Key information
33.7%
Earnings growth rate
33.7%
EPS growth rate
Biotechs Industry Growth | 56.3% |
Revenue growth rate | -1.6% |
Return on equity | 0.4% |
Net Margin | 1.3% |
Next Earnings Update | 17 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How BIOTON makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 182 | 2 | 71 | 6 |
30 Sep 23 | 212 | 2 | 70 | 5 |
30 Jun 23 | 218 | 4 | 67 | 6 |
31 Mar 23 | 217 | 4 | 67 | 6 |
31 Dec 22 | 233 | 1 | 65 | 5 |
30 Sep 22 | 197 | -4 | 63 | 5 |
30 Jun 22 | 188 | 3 | 60 | 5 |
31 Mar 22 | 176 | 5 | 60 | 4 |
31 Dec 21 | 163 | 3 | 60 | 5 |
30 Sep 21 | 212 | 22 | 63 | 5 |
30 Jun 21 | 208 | 20 | 67 | 5 |
31 Mar 21 | 222 | 23 | 74 | 5 |
31 Dec 20 | 222 | 34 | 74 | 4 |
30 Sep 20 | 185 | -24 | 89 | 6 |
30 Jun 20 | 186 | -34 | 94 | 6 |
31 Mar 20 | 208 | -148 | 97 | 6 |
31 Dec 19 | 202 | -127 | 108 | 7 |
30 Sep 19 | 209 | -98 | 108 | 17 |
30 Jun 19 | 213 | -109 | 110 | 23 |
31 Mar 19 | 226 | 76 | 125 | 24 |
31 Dec 18 | 241 | 26 | 134 | 33 |
30 Sep 18 | 294 | 29 | 145 | 38 |
30 Jun 18 | 337 | 47 | 161 | 33 |
31 Mar 18 | 338 | -39 | 157 | 33 |
31 Dec 17 | 362 | -27 | 157 | 25 |
30 Sep 17 | 303 | -31 | 152 | 8 |
30 Jun 17 | 286 | -31 | 149 | 8 |
31 Mar 17 | 279 | -28 | 150 | 7 |
31 Dec 16 | 278 | -16 | 146 | 8 |
30 Sep 16 | 251 | -536 | 143 | 7 |
30 Jun 16 | 289 | -526 | 140 | 6 |
31 Mar 16 | 308 | -522 | 138 | 5 |
31 Dec 15 | 333 | -522 | 136 | 4 |
30 Sep 15 | 417 | 14 | 142 | 3 |
30 Jun 15 | 411 | 10 | 142 | 3 |
31 Mar 15 | 393 | 19 | 138 | 3 |
31 Dec 14 | 377 | 13 | 137 | 4 |
30 Sep 14 | 356 | 4 | 131 | 4 |
30 Jun 14 | 331 | 4 | 126 | 4 |
31 Mar 14 | 330 | -3 | 125 | 4 |
31 Dec 13 | 340 | 0 | 125 | 4 |
30 Sep 13 | 337 | -10 | 126 | 4 |
30 Jun 13 | 342 | -28 | 130 | 4 |
Quality Earnings: BIO has a large one-off gain of PLN19.0M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: BIO's current net profit margins (1.3%) are higher than last year (0.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIO has become profitable over the past 5 years, growing earnings by 33.7% per year.
Accelerating Growth: BIO's earnings growth over the past year (60.1%) exceeds its 5-year average (33.7% per year).
Earnings vs Industry: BIO earnings growth over the past year (60.1%) exceeded the Biotechs industry -11.5%.
Return on Equity
High ROE: BIO's Return on Equity (0.4%) is considered low.